Drugs / Smallpox and Mpox Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04957485 Comparator | Apr 2022 → Jan 2027 expected | smallpox | SIGA Technologies | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Smallpox and Mpox Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04957485 ↗ |
| Modality | Vaccine | “vaccine” NCT04957485 ↗ |
| Route | Subcutaneous | “single AM SC dose of 0.5 mL JYNNEOS on Day 1 and Day 29” NCT04957485 ↗ |